-
Bollinger Ingham and Leigh's Trajenta showed positive results
Time of Update: 2021-02-16
These new data from CAROLINA, as well as data from the placebo-controlled cardiovascular outcome trial CARMELINA, expand liglitatin's evidence and experience and give medical personnel more confidence in the long-term safety of patients treating a wide range of adult type II patients with Trajenta.
-
The new anti-inflammatory drug TYK2 inhibitor BMS-986165 treats moderate to severe plaque psoriasis Phase II clinical:
Time of Update: 2021-02-15
The study was conducted in a multi-center, randomized, double-blind, placebo-controlled, parallel group study in adult patients with moderate to severe plaque-type psoriasis to assess the clinical efficacy and safety of BMS-986165.
-
Shire's new drug has been approved as Europe's first vascular haemophilia recombinant VWF drug
Time of Update: 2021-02-15
Recently, the pharmaceutical company Shire announced that the European Commission (EC) has approved Veyvondi (vonicog alfa) for use in adult patients aged 18 and over with vasovascular haemophilia (VWD) for the treatment of haemorrhage in the single use of deamination (DDAVP) when it is ineffective or not applicable, as well as for the treatment/prevention of surgical bleeding.
-
AstraZeneta immunotoxin Lumoxiti approved by FDA to treat hair cell leukemia (HCL)
Time of Update: 2021-02-15
British pharmaceutical giant AstraZeneca and its global biologics development arm MedImmune recently announced that the U.S. Food and Drug Administration (FDA) has approved Lumoxiti (moxetumomab pasudotox-tdfk) for adult patients with recurring or refractic hair cell leukemia (HCL) who have previously received at least two systematic therapies, including nucleoside analogues.
-
Sanofi/Regenerative new anti-inflammatory drug Dupixent treats adolescent endemic dermatitis (AD) Phase III clinically obtained:
Time of Update: 2021-02-15
Based on the Phase III study data, Sanofi and Regeneratives have filed regulatory filings for the use of Dupixent for moderate to severe AD treatment in adolescents (12-17 years of age).
-
Nanotechnology and mRNA technology, double sword to crack the prostate cancer treatment problem
Time of Update: 2021-02-15
, the study provides a new way to combine mRNA technology with nanotechnology to restore tumor anti-cancer gene function to treat tumors.
-
New drug for leukemia! Pfizer's new Hedgehog pathline inhibitor Daurismo has been approved for first-line treatment of acute myelin white blood:
Time of Update: 2021-02-14
the approval, making Daurismo the first and only HEdgehog signaling pathens inhibitor to be approved by the FDA for the treatment of AML, will provide an important treatment option for a group of incurable patients who are unable to receive intensive chemotherapy due to age or other diseases.
-
New drug for psoriasis! Bryhali (halophetamine, 0.01% emulsion) is available in the United States
Time of Update: 2021-02-14
The safety of Bryhali lotions has been confirmed in clinical studies, patients with a daily local medication for 8 weeks of continuous treatment, showing good tolerance, and no increase in skin atrophy.
-
AstraZeneca and Amtrane's tezepelumab have won the "breakthrough" status
Time of Update: 2021-02-14
Tezepelumab is exciting because it has the potential to treat a wide range of people with severe asthma, including those that are not eligible for currently approved biotherapy," said Sean Bohen, Executive Vice President of Global Pharmaceutical Development and Chief Medical Officer of Arizona.
-
AstraZeneur's clinical late-stage products are expected to be used to treat deadly neurological diseases
Time of Update: 2021-02-14
We believe that in AstraZenecon's Phase 2a study, early signals observed at a 12-week point in time provide a strong reason to initiate a long-term, definitive trial to determine its efficacy and safety in MSA patients.
-
Scientists have developed non-addictive painkillers
Time of Update: 2021-02-14
The main purpose of this study was to design and test a drug that could both act on the main ingredient in the most effective prescription painkillers μ opioid receptors, but also respond to or prevent abuse and dependence on associated pain-sensitive peptide receptors.
-
Scientists have clarified that new mechanisms of action for neurons in the brain promise to develop new therapies for rare immune diseases
Time of Update: 2021-02-14
In a recent study published in the international journal Cell, scientists from institutions such as the University of Geneva successfully described the mechanisms of neurons in the brains of mice or offered new hope for the treatment of Rasmussen encephalitis, after researchers believed that neurons were the target of immune cells that attack synapses ( synapses are connections between neurons) but found that neurons themselves may play a key role in inducing this process.
-
Surprise! A stroke or a cure! This common antidote can actually help stroke recovery!
Time of Update: 2021-02-14
Naloxone, a life-saving drug used to treat opioid poisoning, can reduce brain inflammation in male rats after a stroke.
-
Great news for immunotherapy of liver cancer! Mercadon Keytruda has been approved by the FDA to treat hepatocellular carcinoma
Time of Update: 2021-02-14
The U.S. Food and Drug Administration (FDA) has approved a new adaptation of the PD-1 oncology immunotherapy Keytruda (Chinese commodity name: Corida, common name: Pabli pearl monoantigen) for patients with hepatocellular carcinoma (HCC) who have previously been treated with the targeted drug sorafenib( sorafenib).
-
Phosphromycin is expected to treat the deadly lester bacteria
Time of Update: 2021-02-14
In a recent study published in the international journal PLoS Genetics, scientists from the University of Edinburgh found that bacteria thought to be resistant to powerful antibiotics may eventually b
-
New synthetic peptides to treat AIDS: 99% reduction in viral load in 4 weeks
Time of Update: 2021-02-14
July-August 2018, Zion Medical conducted a Phase I/IIa clinical study in Gamora, which confirmed previous clinical results that the drug is safe and effective in killing HIV-infected cells.
-
CCR has found a new antibody that can effectively treat small cell lung cancer
Time of Update: 2021-02-14
Algae glycosin GM1 neuroglycoside lipids (FucGM1) are tumor-related antigens expressed in a large proportion of small cell lung cancer (SCLC) tumors, but most normal adult tissues lack this substance,
-
Gilead and the Galapagos' Fergtini drug RA trial was successful
Time of Update: 2021-02-14
"These initial Phase III data support the potential of filgotinib, combined with the drugs chosen to regulate disease, to help active rheumatoid arthritis patients who do not adequately respond to current biodemotic modifiers," said John McHutchison, Chief Scientific Officer, Gilead's head of research and development.
-
Europe's first! Novaral CAR-T cell product Kymriah was approved on the same day: ALL and DLBCL
Time of Update: 2021-02-14
In these trials, Kymriah showed strong and long-lasting response rates and consistent safety in two groups of patients who were difficult to treat.
-
Gilead developed a non-alcoholic fatty hepatitis drug to complete the mid-stage trial
Time of Update: 2021-02-14
new data show Gilead's drug is working as expected, but analysts say the results don't look particularly strong compared to Intercept Pharma's Oculus acid, which is already on the market for primary bile cirrhosis (PBC) and stage 3 for patients with non-alcoholic fatty hepatitis cirrhosis.
![9-[1,1'-biphenyl]-4-yl-3,3'-Bi-9H-carbazole](https://file.echemi.com/fileManage/upload/category/ac71ac0d-8ef6-11ec-89e5-fa163ed06441.png)
